Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of Orelabrutinib in relapsing-remitting multiple sclerosis
2020-005117-41Phase 2Completed
- Sponsor
- InnoCare Pharma, Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Orelabrutinib with Placebo (2 arms). Started Jul 2021; status: completed.
02
Drugs
orelabrutinib
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2020-005117-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005117-41.